Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer

Inclusion Criteria:

• Age of 18years or over
• Patients who had failed more than 1 cycle of standard therapy with advanced or metasatic stage and with measurable lesions
• Life expectancy >/= 5 months
• Not available to any of resectable surgery or radiotherapy

• Patients with adequate organ(e.g. heart, kidney, liver)and bone marrow function, as defined by

  1. Absolute neutrophil count(ANC)>/= 1.0 x 10^9/L, Platelet count >/= 75 x 10^9/L
  2. Total bilirubin < 2.0mg/dL
  3. Aspartate Aminotransferase(AST) and/or Alanine Aminotransferase(ALT) < 5 x Upper Limit Normal(ULN)
  4. creatinine < 2 x ULN
• ECOG status 0 to 2
• Female volunteers admitted to the study must be using a reliable means of contraception and must have a negative blood or urine pregnancy test at least 7days ago
• Patients or their legal representatives who have signed the informed consent form.

Exclusion Criteria:

• Known brain or spinal cord metastases
• Patients who have received chemotherapy within the previous 4 weeks
• Patients who have received radiotherapy related tp Gastric cancer within 4weeks
• Patients who have participated in other clinical study within the previous 4weeks
• Pregnancy (absence to be confirmed by ß-hCG test) or lactation period
• Human immunodeficiency virus(HIV) antibody (+)
• Have active infection or serious concomitant systemic disorder incompatible with the study
• Clinically hypertension or diabete mellitus not well controlled with medication
• Clinically significant cardiac disease(e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias) or myocardial infarction
• Presence or history of malignancy other than Gastirc cancer within 5years
• Have severe Neurologic or psychological disorder
• Patients who have history of allery with this investigational drug(SB injection)
• Obvious cognitive or physical impairment that would prevent participation